FierceBiotechOriginal article
{"a":[{"_":"Capricor secures reprieve as FDA extends DMD cell therapy review","$":{"href":"/biotech/capricor-secures-reprieve-fda-extends-dmd-cell-therapy-review","hreflang":"en"}}]}
RegulatoryPositive
AI Analysis
Summary
The FDA extended its review of Capricor Therapeutics' DMD cell therapy candidate, deferring the decision to allow evaluation of newly submitted information following a negative advisory committee vote.
Outcome Details
FDA extended review period to consider additional information submitted after negative advisory committee vote
Importance:6/10
Sentiment:
0.30
FDAcell therapyDMDreview extensionregulatory
Related Companies
Read the original article
Published by FierceBiotech on August 25, 2026 3:27 AM